Back to Studies
IMPAACT 2041
Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in People with Hepatitis C During Pregnancy
Primary Protocol Team Members
Summary
IMPAACT 2041 is a Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in People with Hepatitis C During Pregnancy. The study is designed to evaluate the pharmacokinetics and safety of GLE/PIB during pregnancy and postpartum, and will follow pregnant people and their infants through three months postpartum.
Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...